Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease

被引:92
作者
McNaught, KS
Carrupt, PA
Altomare, C
Cellamare, S
Carotti, A
Testa, B
Jenner, P
Marsden, CD
机构
[1] Univ London Kings Coll, Div Biomed Sci, Pharmacol Grp, Neurodegenerat Dis Res Ctr, London SW3 6LX, England
[2] Univ Lausanne, Ecole Pharm, Inst Chim Therapeut, BEP, Lausanne, Switzerland
[3] Univ Bari, Dipartimento Farmaco Chim, Bari, Italy
[4] Univ London, Dept Clin Neurol, Inst Neurol, Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England
基金
英国惠康基金;
关键词
isoquinoline derivatives; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP); 1-methyl-4-diphenylpyridinium (MPP+); 1,2,3,4-tetrahydroisoquinoline; neurotoxin; Parkinson's disease;
D O I
10.1016/S0006-2952(98)00142-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The cause of neurodegeneration in Parkinson's disease (PD) remains unknown. However, isoquinoline derivatives structurally related to the selective dopaminergic toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its active metabolite, 1-methyl-4-phenylpyridinim (MPP+), have emerged as candidate endogenous neurotoxins causing nigral cell death in Parkinson's disease. Isoquinoline derivatives are widely distributed in the environment, being present in many plants and foodstuffs, and readily cross the blood-brain barrier. These compounds occur naturally in human brain where they are synthesized by non enzymatic condensation of biogenic amines (e.g. catecholamines and phenylethylamine) with aldehydes, and are metabolized by cytochrome P450s and N-methyltransferases. In addition, isoquinoline derivatives are oxidized by monoamine oxidases to produce isoquinolinium cations with the concomitant generation of reactive oxygen species. Neutral and quaternary isoquinoline derivatives accumulate in dopaminergic nerve terminals via the dopamine re uptake system, for which they have moderate to poor affinity as substrates. Several isoquinoline derivatives are selective and more potent inhibitors of NADH ubiquinone reductase (complex I) and a-ketoglutarate dehydrogenase activity in mitochondrial fragments than MPP+, and lipophilicity appears to be important for complex I inhibition by isoquinoline derivatives. However, compared with MPP+, isoquinoline derivatives are selective but less potent inhibitors of NADH-linked respiration in intact mitochondria, and this appears to be a consequence of their rate-limiting ability to cross mitochondrial membranes. Although both active and passive processes are involved in the accumulation of isoquinoline derivatives in mitochondria, inhibition of respiration is determined by steric rather than electrostatic properties. Compared with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or MPP+, isoquinoline derivatives show selective but relatively weak toxicity to dopamine-containing cells in culture and following systemic or intracerebral administration to experimental animals, which appears to be a consequence of poor sequestration of isoquinoline derivatives by mitochondria and by dopamine-containing neurones. In conclusion, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-like cytotoxic characteristics of isoquinoline derivatives and the endogenous/environmental presence of these compounds make it conceivable that high concentrations of and/or prolonged exposure to isoquinoline derivatives might cause neurodegeneration and Parkinson's disease in humans. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:921 / 933
页数:13
相关论文
共 92 条
[1]  
Agid Y., 1987, MOVEMENT DISORD, V2, P166
[2]  
[Anonymous], NEURODEGENERATION NE
[3]   Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: Advantage of a new high-performance liquid chromatography methodology [J].
AntkiewiczMichaluk, L ;
KrygowskaWajs, A ;
Szczudlik, A ;
Romanska, I ;
Vetulani, J .
BIOLOGICAL PSYCHIATRY, 1997, 42 (06) :514-518
[4]   Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease [J].
Bandmann, O ;
Vaughan, J ;
Holmans, P ;
Marsden, CD ;
Wood, NW .
LANCET, 1997, 350 (9085) :1136-1139
[5]   DETERMINATION OF TETRAHYDROPAPAVEROLINE IN THE URINE OF PARKINSONIAN-PATIENTS RECEIVING L-DOPA CARBIDOPA (SINEMET) THERAPY BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
CASHAW, JL .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1993, 613 (02) :267-273
[6]   METABOLISM OF THE NEUROTOXIC TERTIARY AMINE, MPTP, BY BRAIN MONOAMINE-OXIDASE [J].
CHIBA, K ;
TREVOR, A ;
CASTAGNOLI, N .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 120 (02) :574-578
[7]   IRREVERSIBLE INHIBITION OF MITOCHONDRIAL COMPLEX-I BY 1-METHYL-4-PHENYLPYRIDINIUM - EVIDENCE FOR FREE-RADICAL INVOLVEMENT [J].
CLEETER, MWJ ;
COOPER, JM ;
SCHAPIRA, AHV .
JOURNAL OF NEUROCHEMISTRY, 1992, 58 (02) :786-789
[8]   CHANGES IN GLUTATHIONE AND CELLULAR-ENERGY AS POTENTIAL MECHANISMS OF PAPAVERINE-INDUCED HEPATOTOXICITY INVITRO [J].
DAVILA, JC ;
DAVIS, PJ ;
ACOSTA, D .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1991, 108 (01) :28-36
[9]   BIOGENIC AMINE-ALDEHYDE CONDENSATION PRODUCTS - TETRAHYDROISOQUINOLINES AND TRYPTOLINES (BETA-CARBOLINES) [J].
DEITRICH, R ;
ERWIN, V .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1980, 20 :55-80
[10]   INCREASED LEVELS OF LIPID HYDROPEROXIDES IN THE PARKINSONIAN SUBSTANTIA-NIGRA - AN HPLC AND ESR STUDY [J].
DEXTER, DT ;
HOLLEY, AE ;
FLITTER, WD ;
SLATER, TF ;
WELLS, FR ;
DANIEL, SE ;
LEES, AJ ;
JENNER, P ;
MARSDEN, CD .
MOVEMENT DISORDERS, 1994, 9 (01) :92-97